Market Overview

The Medicines Company, Alnylam Announce Global Alliance

Share:
Related MDCO
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says
The Medicines Company Announces FDA Approval of KENGREAL as an Adjunct to Percutaneous Coronary Intervention for Reducing Thrombotic Events
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th! (Seeking Alpha)

The
Medicines Company (NASDAQ: MDCO) and Alnylam
Pharmaceuticals (NASDAQ: ALNY) announced today that they have formed
an exclusive global alliance for the development and commercialization
of Alnylam's ALN-PCS RNAi therapeutic program for the treatment of
hypercholesterolemia.

“This new alliance unites two organizations with a shared culture and
commitment to innovation. In my view and past experience, there could be
no stronger partner for our ALN-PCS program than The Medicines Company,
which has demonstrated industry-wide leadership in the advancement of
cardiovascular medicines to patients and remarkable success in its
strategy of in-licensing, developing, and commercializing breakthrough

See full press release

Posted-In: Earnings News Guidance Contracts Management

 

Related Articles (ALNY + MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters